Código QR (código de barras bidimensional)

A Phase 1 Study of ABI‐009 (Nab‐sirolimus) in Combination With Temozolomide and Irinotecan in Pediatric Patients With Recurrent or Refractory Solid Tumors, Including CNS Tumors—A Children's Oncology Group Pediatric Early Phase Clinical Trial Network Study ADVL1514

ABSTRACT Background Nab‐sirolimus (ABI‐009, nab‐rapamycin; Aadi Bioscience Inc. [Aadi]) is a human albumin‐bound form of sirolimus nanoparticles, a potent mTOR inhibitor. This phase I trial was conducted to define dose‐limiting toxicities (DLT), maximum tolerated or recommended phase II dose (MTD/RP...

Fuld beskrivelse

Na minha lista:
Principais autores: Stuart L. Cramer, Alyssa Terry Reddy, Charles Gene Minard, Stephan Voss, Elizabeth Fox, Xiaowei Liu, Kristina Denic, Joel M. Reid, Brenda J. Weigel
Format: Artigo
Sprog:Inglês
Udgivet: Wiley 2024-11-01
Serier:Cancer Medicine
Fag:
ABI‐009
Clinical trial
nab‐rapamycin
Pediatrics
rapamycin
Online adgang:https://doi.org/10.1002/cam4.70376
Tags: Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!

Lignende værker